AMGN241115P335000
- 40.15
- +27.10+207.66%
Amgen Newsroom
Wolfe Research Maintains Amgen(AMGN.US) With Hold Rating
Evercore Maintains Amgen(AMGN.US) With Buy Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $335 to $383
Amgen Analyst Ratings
HSBC Adjusts Price Target on Amgen to $385 From $369
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $362 to $405
Amgen Analyst Ratings
Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $322 to $383
Amgen Is Maintained at Neutral by UBS
Amgen Analyst Ratings
Goldman Sachs Adjusts Price Target on Amgen to $375 From $369, Maintains Buy Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $322 to $405
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $335
Bernstein Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Navigating 14 Analyst Ratings For Amgen